Keystone Realtors reported lower quarterly profit due to legacy projects, while revenue, pre-sales and project additions recorded strong growth
The diversified Bajaj group, having interests in auto and financial services, turned 100 years old on Monday. Prime Minister Narendra Modi lauded the group's work through the decades, noting that it has helped in the cause of nation-building. "Over the decades, the Bajaj Group has played an important role in nation-building by creating jobs, fostering innovation and supporting community development," Modi said in a congratulatory message. The group celebrated with an event in central Mumbai on Monday that was attended by a slew of politicians, business people and others. Founded in 1926 in Mumbai by Jamnalal Bajaj, who was also actively involved in the freedom struggle and is considered the fifth adopted son of Mahatma Gandhi, the group now has a market capitalisation of USD 148 billion and employs 1.3 lakh people. Amid the greater thrust on domestic manufacturing, Niraj Bajaj, the chairman of Bajaj Auto, reminded that India's journey towards self-reliance did not begin recently,
Rural-focused microfinance institution Sindhuja Microcredit on Monday said it has raised USD 5 million (Rs 47 crore) in a pre-series D funding round from its existing investors. The funding round saw participation from Abler Nordic, GAWA Capital (through its vehicle Huruma Fund) and Oikocredit, the company said in a statement. The Noida-headquartered NBFC-MFI will utilise the fresh capital to strengthen its capital base, support business expansion, and scale up access to credit for underserved communities. "We are making significant progress in our mission in touching the lives of low-income women borrowers from under-served households as well as in making financial services accessible to the financially excluded and MSME entrepreneurs through efficient, customer-friendly and technology-enabled solutions," Sindhuja Microcredit Co-Founders Abhisheka Kumar and Malkit Singh Didyala said in a joint statement. "The latest funds will drive us to the next phase of growth by further expand
M P Birla Group firm Birla Corporation Ltd on Saturday reported a consolidated net profit of Rs 294.77 crore in the March quarter of 2025-26 on a year-on-year basis. It had posted a net profit of Rs 256.6 crore for the January-March period a year ago, according to a regulatory filing from Birla Corporation. However, Birla Corporation's revenue from operations was marginally up at Rs 2,836.12 crore in the March quarter of FY26. It was at Rs 2,814.91 crore in the corresponding period a year ago. This was "owing to poor realisation from the cement business and external shocks affecting the performance of Birla Jute Mills," said Birla Corporation in its earnings statements. Total expenses of Birla Corporation were at Rs 2,522.18 crore, up 1 per cent in the March quarter. Birla Corporation's revenue from the Cement business was marginally up to Rs 2,716.06 crore in the fourth quarter of FY'26. It was at Rs 2,691.84 crore in the corresponding quarter. Its cement sales by volume grew by
L&T has secured its largest domestic metals-sector order from JSW Steel to build critical facilities as the steelmaker expands capacity in Ballari and Paradip
L&T posts marginal decline in Q4 profit due to base effect, while revenue grows 11% on strong order inflow; board recommends Rs 38 per share dividend
The Bombay High Court on Tuesday quashed a bribery case against HDFC Bank MD and CEO Sashidhar Jagdishan filed by the Lilavati Kirtilal Mehta Medical Trust, calling the complaint a "counterblast" to the bank's recovery proceedings to reclaim dues of over Rs 65 crore. A division bench of Justices M S Karnik and N R Borkar stated that financial institutions are bound to initiate proceedings for recovery of loan amounts, and observed that the complaint was a result of the acrimony and strained relations between the Trust's past and present trustees. Lilavati Kirtilal Mehta Medical Trust runs Lilavati Hospital in Bandra. "In our view, the complaint is nothing but a counterblast to the recovery proceedings initiated, and the materials on record do not at all justify an investigation into the claim made by the complainant," the court said. It also refused to accept the complainant's claim that the Trust's founder, Kishore Mehta, died in 2024 because of pressure mounted by the bank and sa
Board appoints KM Birla as Non-Executive Chairman as Vodafone Idea benefits from AGR relief and prepares for fundraising and network expansion
Ajanta Pharma Ltd on Tuesday reported a 18.4 per cent rise in consolidated net profit at Rs 266.7 crore in the fourth quarter ended March 31, on the back of strong US generics revenue growth. The company had posted a consolidated net profit of Rs 225.26 crore in the corresponding period previous fiscal, Ajanta Pharma Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 1,421.64 crore as against Rs 1,170.41 crore in the year-ago period, it added. During the quarter branded generics in the markets of India, Asia and Africa clocked a combined revenue of Rs 859 crore as compared to Rs 805 crore in the year-ago period, up 7 per cent. US generic revenue was at Rs 505 crore as compared to Rs 325 crore in the same period a year ago, up 56 per cent, the company said. Total expenses in the fourth quarter were higher at Rs 1,135.96 crore as compared to Rs 919.11 crore in the same period a year ago, the company said. For FY26, consolidated n
BENGALURU, May 5 - India's Larsen & Toubro posted a 3.1% fall in quarterly profit on Tuesday, as the Middle East war disrupted he infrastructure giant's projects in the region.
Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at Rs 243.74 crore in the fourth quarter ended March 2026 on the back of robust growth in international business. The company had posted a consolidated net profit of Rs 197.24 crore in the corresponding quarter last fiscal, Emcure Pharmaceuticals Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 2,469.7 crore as against Rs 2,116.25 crore in the same period a year ago, it added. International business sales were at Rs 1,493 crore, up 25.7 per cent YoY, with strong growth across markets supported by base business ramp-up and new launches, Emcure Pharma said. On the other hand, domestic business sales were at Rs 977 crore, up 5.2 per cent YoY. Softer performance was largely due to the Zuventus portfolio and team reorganisation, it added. Zuventus is a subsidiary of the company. Total expenses in the fourth quarter were higher at Rs ..
Private sector lender CSB Bank on Monday reported a 6 per cent year-on-year rise in its profit after tax to Rs 202 crore in the three months ended March 2026, driven by higher core income. The Kerala-based lender had posted a PAT (profit after tax) of Rs 190 crore in the year-ago period. The bank's Net Interest Income (NII) or core income jumped 25 per cent year-on-year to Rs 464 crore in the quarter under review from Rs 371 crore in the January-March quarter of the preceding fiscal (Q4 FY25), CSB Bank said in a regulatory filing. Total income increased to Rs 1,507 crore in Q4FY26 from Rs 1,362.36 crore a year ago. On the asset quality front,the Gross non-performing assets (GNPA) ratio improved to 1.66 per cent by March 31, 2026 from 1.57 per cent in March 2025, while Net NPA also fell significantly to 0.40 per cent from 0.52 per cent over the same period. "Q4 FY26 marked the best quarter in terms of asset quality, with GNPA and NNPA ratios at their lowest levels for the year," CS
Aditya Birla Capital on Monday reported a 31 per cent growth in consolidated profit at Rs 1,129 crore for the fourth quarter ended March 31 on higher interest income. The financial services company had profit attributable to owners of the company from total operations on consolidated basis at Rs 865 crore in the January-March period of 2024-25. Interest income rose to Rs 5,516 crore during the March quarter of FY26, from Rs 4,481 crore in the corresponding period a year ago. Total revenue from operations rose to Rs 13,459 crore at the end of March quarter of 2025-26 fiscal, from Rs 12,214 crore in the March quarter of FY25. For the full FY26 fiscal, Aditya Birla Capital reported a consolidated profit of Rs 3,764 crore, a 13 per cent rise against Rs 3,332 crore in FY25. Total revenues in FY26 stood at Rs 45,509 crore, up from Rs 40,590 crore in FY25. Shares of Aditya Birla Capital closed at Rs 348.10, up 0.80 per cent over previous close on BSE.
Global product engineering and digital services firm Tata Technologies Ltd on Monday reported an 8 per cent increase in consolidated net profit to Rs 204.17 crore during the March quarter. The company had posted a consolidated net profit of Rs 188.87 crore in the corresponding quarter of the previous fiscal year, Tata Technologies Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter was at Rs 1,572.22 crore as compared to Rs 1,285.65 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 1,382.62 crore as compared to Rs 1,088.2 crore in the year-ago period, it added. For FY26, consolidated net profit was at Rs 546.59 crore as compared to Rs 676.95 crore in FY25. Consolidated revenue from operations in FY26 stood at Rs 5,505.57 crore as against Rs 5,168.45 crore in FY25, the company said. Commenting on the performance, Tata Technologies Ltd CEO & MD Warren Harris said the company has been able carry ...
Jindal Stainless on Monday posted over 41 per cent growth in consolidated net profit to Rs 834.21 crore during the quarter ended March 31, driven by higher revenues. The company had reported a net profit of Rs 589.96 crore in the year-ago period, according to an exchange filing. During the fourth quarter, the company's total income rose to Rs 11,427.91 crore from Rs 10,292.27 crore in the January-March period of the preceding 2024-25 financial year. For the entire FY26, the company's net profit jumped to Rs 3,184 crore from Rs 2,499.72 crore in the year ago. Total income rose to Rs 43,306.14 crore during the fiscal ended March 2026, from Rs 39,603.06 crore in 2024-25 financial year.
Net interest income (NII) grew 8 per cent Y-o-Y to Rs 7,876 crore, supported by strong loan growth; standalone net profit was up 13 per cent Y-o-Y
Central Depository Services (India) Ltd on Saturday said its consolidated net profit stood at Rs 80 crore in the March quarter of 2025-26 against Rs 100 crore in the year-ago period. Total income during the quarter was Rs 268 crore as against Rs 256 crore in the same quarter of FY25, a company statement said. For the full 2025-26 fiscal, net profit was Rs 455 crore against Rs 526 crore in the previous 2024-25 financial year. Total consolidated income rose to Rs 1,239 crore in FY26 against Rs 1,199 crore in FY25, CDSL said. The company said that it became the first depository to register 18 crore-plus demat accounts as of March 31, 2026, extending the trajectory from 15.30 crore accounts as of March 31, 2025. Nehal Vora, Managing Director & Chief Executive Officer, said, "FY26 stands as a defining year in our journey of empowering India's Atmanirbhar Investors. "Surpassing 18 crore demat accounts reflects not merely scale, but the deepening trust of Indian households in the ...
Generic drug maker Hindustan Laboratories and steel tubes and pipes manufacturer RK Steel Manufacturing Company have secured Sebi's approval to raise funds through initial public offerings (IPOs), an update with the markets regulator showed on Thursday. The two companies, which filed their preliminary IPO papers in September, obtained Sebi's observations on April 27. In Sebi's parlance, obtaining observations is equivalent to securing approval to float a public offering. Hindustan Laboratories' maiden public offering comprises a fresh issue of 50 lakh shares, along with an offer for sale (OFS) of 91 lakh shares by the promoter, according to the draft red herring prospectus (DRHP). The company proposes to utilise IPO proceeds for funding the working capital requirements and general corporate purposes. Hindustan Laboratories is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a ...
AI-powered tool enables enterprises to scan codebases for vulnerabilities and generate patches, with global tech and consulting partners supporting deployment
DoT committee finalises AGR reassessment, with most dues to be paid in instalments between FY36 and FY41, extending relief to the financially stressed telecom operator